fbpx

Marsha Ames lived in Topeka Kansas with her family of six, a happy homemaker married to a steel shed company executive. Their lovely single family residence was on a corner of a street in suburban Topeka that could have been the setting for a Hallmark channel movie. Life was good; the future bright.

Then she went to her doctor for a routine exam and they dianosed her with stage 3 lymph node cancer. She was given six months to live, tops.

The shock wave was instantaneous. Her husband located the very best doctor he could find, at the best facilities. They told her there was little beyond conventional chemotherapy they could do. He pressed, and found a doctor in their research department who was experimenting with a new form of proton laser that had show some hope in a few cases. They asked the cost.

Although President Trump’s new law allowing experimental techniques was in effect, insurance companies were not compelled nor required to cover experimental techniques. They had to find over $500,000 somehow, some way.

They considered a home loan, but they had just moved into their home that Spring, so there was no equity in it yet. They could go for a personal loan, but without an asset to back it no bank would extend a loan of that size even with his excellent credit.

He had over $1M in stocks and bonds, but this was the family’s nest egg, designed to help cover the kids future college costs. Sacrificing their future for his wife was something neither he nor his wife could accept doing.

His stock portfolio was diverse and of a solid quality, with bonds, stocks and mutual funds equally distributed. But over the past three years of a booming economy and stock market, it had increased in value almost 50 percent – which meant a huge capital gains tax hit if he sold them.

Desperate, he went online and eventually found A. B. Nicholas Securities Finance, the specialists in securiites portfolio lending programs. We obtained a loan for $750,000 at 3.5%, interest-only required, and delivered it in a matter of days. All without selling a single share or foregoing their children’s inheritance, giving them unlimited time to repay as it is a revolving line of credit.

Six months later amazed doctors declared Marsha cancer-free. Several remarked that they’d never seen a case of complete remission in a person with advanced lymph node cancer. Yet, there it was, the result of a brave new therapy and a loan from A. B. Nicholas that literally saved a life…

Apply today for your LeverageLine!

Share on facebook
Facebook
Share on google
Google+
Share on twitter
Twitter
Share on linkedin
LinkedIn
Related Posts

View Our New REITLINE Video Today

Add New PostOur REITLine loan program allows individuals with normally unsellable UPREIT securities to obtain cash via credit line against their portfolio. Previously, real estate investors who received payment for the sale of their property in UPREIT tax-deferred securities could not obtain cash from that sale unless they converted the UPREIT to a normal marketable REIT, a typically costly process in the sale automatically becomes taxable when this is done.With

New, Super-Low Fixed Rates from A. B. Nicholas!

A. B. Nicholas is happy to announce new fixed rates for all stock loans for portfolios of at least $80,000 in initial value. With Loan-to-Value that is the best in the U. S. market (up to 97%) in a licensed, secure, institutional credit line, we now offer via our partner firms the lowest rates in the industry for fixed-rate stock loans. Our latest fixed-rate promotions.  Starting today… 3 year fixed

A. B. Nicholas now offers competitive bids from four major firms for all stock loan applicants.

A. B. Nicholas is happy to announce the additon of our fourth funding partner, E-Trade, as a bidder for our stock loan applicants via the ABN LeverageLine program.  Now our clients with eligible portfolios (see our requirements here) may receive stock loan bids from up to four — soon to be five — major firms in a “let the stock loan lenders compete” process that can get ABN borrowers superior,

Join Our Weekly Newsletter

We do not sell, communicate or divulge your information to any third-parties.